By Sabela Ojea
iBio on Monday announced a 20-to-1 reverse stock split. Shares of the biopharmaceutical company declined 8.6% to 26 cents in after-hours trading.
Acelyrin said there was a programming error in its drug trial of a treatment for psoriatic arthritis. Shares of the biopharmaceutical company dropped 9% to $7.92 in after-hours trading.
…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here